Clinical trial
Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy
NCT00041795 · NeoTherapeutics, Industry · Completed
Key facts
| NCT number | NCT00041795 |
|---|---|
| Title | Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy |
| Official title | A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer |
| Lead sponsor | NeoTherapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral Nervous System Diseases, Chemotherapy-Induced Peripheral Neuropathy |
| Intervention type | Drug |
| Interventions | leteprinim potassium (Neotrofin) |
| Enrollment | 50 |
| Start date | Jan 1, 2002 |
| First posted | Jul 19, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: